Inhibrx Biosciences Inc.
INBX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.8B
$121.17
▼ -0.89%
P/E
-13.65
Mkt Cap
$1.8B
52-Wk Range
$26.19–$155.29
52-Week Range
$26.19 - $155.29
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 316.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary protein engineering platform enabling multivalent therapeutic design
- Differentiated mechanism of action targeting validated cancer pathways
- Clinical-stage pipeline with multiple ongoing Phase 2 trials across solid tumors
Bear Case
1 risk
- Very high volatility (beta 3.7). Expect 3x market swings. Position size accordingly.
Growth
Stable outlook
Clinical trial progression and potential regulatory approvals for INBRX-109 and INBRX-106
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+36.0% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying INBX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 13, 2026
Reported EPS of -$2.34 vs -$2.28 consensus (-2.6% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.6%
Revenue trend · last 8Q
—
-94%
—
—
—
-100%
—
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$100.0K
$0
$1.3M
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 27, 2026
vs Industry
How INBX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related